REL-1017 (dextromethadone)

Our most-advanced new chemical entity, d-methadone (dextromethadone, REL-1017), is a novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of depression, CNS, ophthalmological disorders and/or other potential indications. As a single isomer of racemic methadone, d-Methadone has been shown to possess NMDA receptor antagonist properties with virtually no opioid activity or ketamine-like toxicities at the expected therapeutic doses.

d-Methadone Timeline

Indication 2018 2019
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Major Depressive Disorder Rel-1017 Ph2aCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarter
Rett Syndrome PreclinicalCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarter
Ophthalmology Formulation & PreclinicalCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarter
Mitochondrial Diseases / ALS PreclinicalCandidate profile is in development at this time.Candidate profile is in development at this time.Candidate profile is in development at this time.Development of this candidate profile is expended to end at this timeCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarterCandidate is not in development in this quarter
*Depends on preclinical results, FDA feedback and available capital resources.
Clinical
Preclinical